Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Globe Newswire•12/11/2026•16:05 ET
0
Key Highlights
- ➤$142.6 million cash, equivalents and investments expected to fund operations through mid-2028
- ➤FORTIFY enrollment advances ahead of schedule; interim data expected in 2027
- ➤PLN-101095 Phase 1 biomarker data linked early immune activation with subsequent clinical response
- ➤Preclinical studies showed over 75% target gene knockdown at eight weeks in non-human primates
- ➤Third-quarter net loss narrowed to $24.4 million from $26.3 million year over year
Expert Statements
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform”
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“FORTIFY continues to enroll ahead of schedule, with a number of European sites onboarded during the quarter.”
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“In addition, we continue to explore the potential of our proprietary drug delivery platform with cross-species preclinical data demonstrating successful selective delivery of siRNA payloads to extrahepatic tissues.”
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“With emerging data continuing to inform our next steps, potential therapeutic applications and paths forward, we will provide a comprehensive overview of the program in the coming months.”
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment
Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results
Get started
Create a free account to read the full story.